Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671554 · ClinicalTrials.gov registry record · Phase 1
Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma
A Phase 1 study, sponsored by Prisma Health-Upstate.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00671554 is a Phase 1 study that was terminated before completion, run by Prisma Health-Upstate. The registered enrollment target is 3 participants.
The verdict
NCT00671554, a Phase 1 study, was terminated before completion, sponsored by Prisma Health-Upstate.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with the autologous cellular vaccine, Melaxin, in combination with Bacillus Calmette-Guerin (BCG) injections is effective in Stage IV malignant melanoma.
Interventions
- BIOLOGICAL Melaxin (autologous dendritoma vaccine) and BCG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671554
The ClinicalTrials.gov registry entry for NCT00671554 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Melaxin (autologous dendritoma vaccine) and BCG is the first listed.
NCT00671554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671554 about?
NCT00671554 is a clinical study titled "Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma". The purpose of this study is to determine if treatment with the autologous cellular vaccine, Melaxin, in combination with Bacillus Calmette-Guerin (BCG) injections is effective in Stage IV malignant melanoma.
What is the current status of trial NCT00671554?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2008-04. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00671554?
The interventions under investigation include: Melaxin (autologous dendritoma vaccine) and BCG (BIOLOGICAL).
Who is sponsoring clinical trial NCT00671554?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.